Skip to main content
. 2023 May 30;14(6):841–845. doi: 10.1021/acsmedchemlett.3c00169

Table 1. Structures and Selected Data of Topical JAK Inhibitors in Clinical Trials in Atopic Dermatitis.

graphic file with name ml3c00169_0005.jpg

  tofacitiniba delgocitinibb ruxolitinibb CEE321c
cellular potencyd INFa (JAK1/TYK2) 68 42 65 85
whole blood potencyd IL2 (JAK1/3) 30 30 329 2349
Clinte <25 <25 40 166
a

Phase 2.

b

Approved.

c

Phase 1.

d

IC50 [nM], assay protocols in the Supporting Information.

e

Intrinsic clearance in human liver microsomes [μL/min mg].